NCT04433689

Brief Summary

It is known that intraocular pressure changes during pregnancy. Collagen structure changes during pregnancy to enable softening of the symphysis, whitening of the birth chanel, and, thus, ultimately to enable delivery of a child. The cornea consists of highly structured collagen fibers. Hence, it seams logically that corneal biomechanics also change during pregnancy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
4.4 years until next milestone

First Submitted

Initial submission to the registry

June 11, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 16, 2020

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2021

Completed
Last Updated

June 22, 2020

Status Verified

June 1, 2020

Enrollment Period

5 years

First QC Date

June 11, 2020

Last Update Submit

June 18, 2020

Conditions

Keywords

pregnancycorneal biomechanical propertiesintraocular pressure

Outcome Measures

Primary Outcomes (5)

  • Change in Deformation Amplitude

    Change in Deformation Amplitude (in millimeters) at 3 month post delivery compared to during third trimester will be assessed.

    at 3 month post delivery compared to during third trimester

  • Change in Applanation Length

    Change in Applanation Length (in millimeters) at 3 month post delivery compared to during third trimester of the pregnancy will be assessed.

    at 3 month post delivery compared to during third trimester of the pregnancy

  • Change in Corneal Velocity

    Change in Corneal Velocity (in meters/second) at 3 month post delivery compared to during third trimester of the pregnancy will be assessed.

    at 3 month post delivery compared to during third trimester of the pregnancy

  • Change in corneal thickness

    Change in corneal thickness (in millimeters) at 3 month post delivery compared to during third trimester of the pregnancy will be assessed.

    at 3 month post delivery compared to during third trimester of the pregnancy

  • Change in Intraocular pressure

    Change in intraocular pressure (in millimeters of mercury, mmHg) at 3 month post delivery compared to during third trimester of the pregnancy will be assessed.

    at 3 month post delivery compared to during third trimester of the pregnancy

Study Arms (1)

Pregnant women

Pregnant woman, age 18 to 38 yo, with uncomplicated singleton pregnancy and no ocular diseases.

Device: Non-Contact measurement of corneal properties

Interventions

Corneal Properties will be measurement with the non-contact Corvis ST Air-Puff Tonometer by Oculus Inc.

Pregnant women

Eligibility Criteria

Age18 Years - 38 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailsfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

healthy pregnant women with uncomplicated singleton pregnancy

You may qualify if:

  • females
  • pregnant
  • age 18 to 38 yo
  • uncomplicated singleton pregnancy

You may not qualify if:

  • any history of ocular disease or surgery other than conjunctivitis, especially no history of glaucoma or corneal disease
  • systemic diseases, i.e. diabetes, hypertension, collagenase
  • current contact lens wear
  • before pregnancy taking any systemic or ocular medications

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Ophthalmology

Zurich, Canton of Zurich, 8091, Switzerland

RECRUITING

Study Officials

  • Marc Toeteberg-Harms, MD, FEBO

    University Hospital Zurich, Dpt. of Ophthalmology

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Marc o Toeteberg-Harms, MD, FEBO

CONTACT

Belgin o Özsoy, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 11, 2020

First Posted

June 16, 2020

Study Start

January 1, 2016

Primary Completion

December 31, 2020

Study Completion

January 31, 2021

Last Updated

June 22, 2020

Record last verified: 2020-06

Data Sharing

IPD Sharing
Will not share

Locations